Panitumumab as first‑line treatment of colorectal cancer

04/2019

MUDr. Stanislav Batko

Onkologická klinika 2. LF UK a FN v Motole, Praha

SUMMARY

This article reviews the efficacy panitumumab in the 1^st line systemic treatment of metastatic colorectal carcinoma (mCRC). First study published was PRIME in which panitumumab plus FOLFOX compared to chemotherapy alone prolonged overall survival in patients with nonresectable mCRC, furthermore it showed trend towards higher resection rate in patients with liver limited disease. The PEAK trial was comparing panitumumab and bevacizumab with chemotherapy backbone. Both overall survival and progression-free survival favored panitumumab compared to bevacizumab. PLANET trial was exploring potential of panitumumab to enhance overall response rate and allow for more curative resections in LLD population of mCRC patients. PLANET trial provided evidence high resectability and long overall survival. VOLFI trial represents a reasoned step in searching for more potent combination therapy. In randomized manner it compared FOLFOXIRI alone to FOLFOXIRI plus panitumumab. This study met its primary point, which was objective response rate, furthermore it showed greatly increased resectability in panitumumab arm and suggested better overall survival. Panitumumab plus FOLFOXIRI pose viable and efficient option for patients with mCRC, where deep tumor response could open way to surgical resection.

Key words

panitumumab, PRIME, PLANET, PEAK, VOLFI, 1^st line therapy, metastatic colorectal cancer, resectability, ORR, OS, PFS, LLD